Corneal and retinal angiogenesis are driven by vascular endothelial growth factor (VEGF) and are key events in corneal transplant rejection, trauma, age-related macular degeneration, and diabetic retinopathy. We propose to suppress VEGF using an intracellular, anti-angiogenic strategy relying on plasmids which express Flt23k intraceptors, recombinant subunits of Flt-1 (VEGF receptor 1) domains 2 and 3 coupled with KDEL at C-terminal which sequester VEGF within cells, in concert with a targeted nanoparticle delivery system. We previously demonstrated biodegradable, nontoxic, albumin nanoparticles containing plasmids expressing Flt-intraceptors sustained angioinhibition for up to 6 weeks. We will now advance nanoparticle delivery through conjugation with transferrin (to facilitate topical delivery) or with arginine-glycine-aspartic acid (RGD) oligopeptides (to home to neovascular tissues). Targeted delivery of anti-angiogenics to block VEGF intracellularly selectively in neovascular tissues is a significant unmet medical need as recent data indicate that long-term use of intravitreal ranibizumab (the widely used anti-VEGF Fab fragment, which binds VEGF extracellularly) is associated with a 30% risk of developing geographic atrophy within 2 years and over 50% risk at 7 years. We hypothesize that targeted expression of Flt23K "intraceptors", will inhibit corneal transplant rejection and choroidal neovascularization, while mitigating development of fibrosis or atrophy.
Our specific aims are to determine whether: 1. Plasmids expressing intraceptors will inhibit angiogenesis and rejection of corneal transplants. We will test delivery using subconjunctival injections or topical delivery of nanoparticles designed to cross the corneal epithelium. 2. Targeted nanoparticles delivering plasmids expressing intraceptors can inhibit and regress choroidal neovascularization (CNV) in laser-induced and transgenic models. 3. Long-term nanoparticle expression of intraceptors affects tissue re-epithelialization in corneal transplant and tissue fibrosis or atrophy in CNV models.

Public Health Relevance

The project seeks to determine whether very small particles encapsulating a drug can block the development of vision-threatening new vessels (angiogenesis) at the cellular level in for the protection of corneal transplants and age-related macular degeneration (AMD). This study will demonstrate the potential of nanoparticles for long-term therapy;either as a topical drop (for corneal disease) or targeted intravenous injection (for AMD), resulting in new treatments which avoid the risks of current standard of care treatments (injections inside the eye) and improve outcomes for patients.

National Institute of Health (NIH)
National Eye Institute (NEI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (DPVS)
Program Officer
Mckie, George Ann
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Utah
Schools of Medicine
Salt Lake City
United States
Zip Code
Zhang, Xiaohui; Das, Subrata K; Passi, Samuel F et al. (2015) AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization. Mol Ther 23:226-34
Cahoon, Judd M; Olson, Paul R; Nielson, Spencer et al. (2014) Acridine orange leukocyte fluorography in mice. Exp Eye Res 120:15-9
Chennamaneni, Srinivas Rao; Mamalis, Christina; Archer, Bonnie et al. (2013) Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation. J Control Release 167:53-9
Luo, Ling; Zhang, Xiaohui; Hirano, Yoshio et al. (2013) Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano 7:3264-75
Cho, Yang Kyung; Uehara, Hironori; Young, Jason R et al. (2012) Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci 53:2328-36
Qazi, Yureeda; Stagg, Brian; Singh, Nirbhai et al. (2012) Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci 53:2837-44
Kleinman, Mark E; Kaneko, Hiroki; Cho, Won Gil et al. (2012) Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther 20:101-8
Tarallo, Valeria; Hirano, Yoshio; Gelfand, Bradley D et al. (2012) DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149:847-59
Kaneko, Hiroki; Dridi, Sami; Tarallo, Valeria et al. (2011) DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471:325-30
Uehara, Hironori; Luo, Ling; Simonis, Jacquelyn et al. (2010) Anti-SPARC oligopeptide inhibits laser-induced CNV in mice. Vision Res 50:674-9

Showing the most recent 10 out of 13 publications